Global Gastroparesis Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Gastroparesis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Gastroparesis Type, Drug Class Type, and Distribution Channel" report has been added to ResearchAndMarkets.com's offering.

According to this report the market is expected to reach US$ 6,025.11 million by 2027 from US$ 4,338.61 million in 2019; it is estimated to grow at a CAGR of 4.3% from 2020 to 2027. The report highlights trends prevailing in the market, and the factors driving and hindering the market growth. The market growth is primarily attributed to the increasing diabetes prevalence and growing geriatric population. However, side-effects of gastroparesis drugs restrain the growth of the market.

On the basis of type, the gastroparesis market is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic type held the largest share of the market in 2019; however, the market for the diabetic type is estimated to grow at the highest CAGR during the forecast period. The rising number of research and development activities pertaining to the management of diabetic gastroparesis is estimated to offer lucrative opportunities for the growth of the market for the diabetic segment.

The COVID-19 pandemic has disrupted the supply chain of over-the-counter (OTC) and prescription drugs, and this is likely to limit the market growth in the next few quarters. Moreover, the emphasis of health care providers and medical industries on COVID-19 has led to the lowered focus on the diagnosis and treatment for gastroparesis, which is limiting the market growth to a certain extent.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the gastroparesis market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global gastroparesis market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Market Dynamics

Drivers

• Rising Diabetes Mellitus Prevalence
• Increasing Geriatric Population

Restraints

• Side Effects of Gastroparesis Drugs

Opportunities

• Surging Investments and Financial Assistance for Research

Future Trends

• Emphasis on Gastric Electrical Stimulation Therapy Research

Companies Mentioned

• EVOKE PHARMA
• Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
• Johnson and Johnson Services, Inc.
• Allergan Plc
• NEUROGASTRX, INC.
• TEVA PHARMACEUTICAL INDUSTRIES LTD
• Pfizer Inc.
• ANI Pharmaceuticals, Inc.
• Ipca Laboratories Ltd.
• Cinrx Pharma, LLC (Cindome Pharma)

For more information about this report visit https://www.researchandmarkets.com/r/f7fgyk

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900